Literature DB >> 16998505

ATM and breast cancer susceptibility.

M Ahmed1, N Rahman.   

Abstract

ATM was originally identified by positional cloning as the gene that underlies the autosomal recessive condition ataxia-telangiectasia. The encoded protein plays a central role in the complex processes that repair DNA double-strand breaks. Nearly 20 years ago, epidemiological surveys of relatives of ataxia-telangiectasia cases suggested that female relatives were at modestly increased risk of breast cancer. Subsequently, many studies have tried to clarify the role of ATM in breast cancer susceptibility, but have produced inconclusive and/or inconsistent results. Recently, large epidemiological and molecular studies have finally provided conclusive evidence that ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16998505     DOI: 10.1038/sj.onc.1209873

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  71 in total

Review 1.  Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence.

Authors:  Ben Zhang; Alicia Beeghly-Fadiel; Jirong Long; Wei Zheng
Journal:  Lancet Oncol       Date:  2011-04-20       Impact factor: 41.316

Review 2.  Recent advances in the genetics of cerebellar ataxias.

Authors:  Anna Sailer; Henry Houlden
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

3.  Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer.

Authors:  Dokyoon Kim; Ruowang Li; Scott M Dudek; Marylyn D Ritchie
Journal:  J Biomed Inform       Date:  2015-06-03       Impact factor: 6.317

Review 4.  Next-generation sequencing for inherited breast cancer risk: counseling through the complexity.

Authors:  Irene R Rainville; Huma Q Rana
Journal:  Curr Oncol Rep       Date:  2014-03       Impact factor: 5.075

5.  ATM is required for SOD2 expression and homeostasis within the mammary gland.

Authors:  Lisa M Dyer; Jessica D Kepple; Lingbao Ai; Wan-Ju Kim; Virginia L Stanton; Mary K Reinhard; Lindsey R F Backman; W Scott Streitfeld; Nivetha Ramesh Babu; Nicolai Treiber; Karin Scharffetter-Kochanek; Peter J McKinnon; Kevin D Brown
Journal:  Breast Cancer Res Treat       Date:  2017-08-28       Impact factor: 4.872

6.  Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer.

Authors:  Rosa Murria; Sarai Palanca; Inmaculada de Juan; Cecilia Egoavil; Cristina Alenda; Zaida García-Casado; María J Juan; Ana B Sánchez; Ana Santaballa; Isabel Chirivella; Ángel Segura; David Hervás; Marta Llop; Eva Barragán; Pascual Bolufer
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

7.  Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer.

Authors:  Jinliang Xing; Xifeng Wu; Ara A Vaporciyan; Margaret R Spitz; Jian Gu
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

8.  Hemizygosity for Atm and Brca1 influence the balance between cell transformation and apoptosis.

Authors:  Fengtao Su; Lubomir B Smilenov; Thomas Ludwig; Libin Zhou; Jiayun Zhu; Guangming Zhou; Eric J Hall
Journal:  Radiat Oncol       Date:  2010-02-22       Impact factor: 3.481

9.  DNA Repair Gene Expression Levels as Indicators of Breast Cancer in the Breast Cancer Family Registry.

Authors:  Maya A Kappil; Yuyan Liao; Mary Beth Terry; Regina M Santella
Journal:  Anticancer Res       Date:  2016-08       Impact factor: 2.480

10.  Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene.

Authors:  Jirina Bartkova; Johanna Tommiska; Lenka Oplustilova; Kirsimari Aaltonen; Anitta Tamminen; Tuomas Heikkinen; Martin Mistrik; Kristiina Aittomäki; Carl Blomqvist; Päivi Heikkilä; Jiri Lukas; Heli Nevanlinna; Jiri Bartek
Journal:  Mol Oncol       Date:  2008-10-07       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.